Effects of type I interferons on Friend retrovirus infection.
The type I interferon (IFN) response plays an important role in the control of many viral infections. However, since there is no rodent animal model for human immunodeficiency virus, the antiviral effect of IFN-alpha and IFN-beta in retroviral infections is not well characterized. In the current study we have used the Friend virus (FV) model to determine the activity of type I interferons against a murine retrovirus. After FV infection of mice, IFN-alpha and IFN-beta could be measured between 12 and 48 h in the serum. The important role of type I IFN in the early immune defense against FV became evident when mice deficient in IFN type I receptor (IFNAR(-/-)) or IFN-beta (IFN-beta(-/-)) were infected. The levels of FV infection in plasma and in spleen were higher in both strains of knockout mice than in C57BL/6 wild-type mice. This difference was induced by an antiviral effect of IFN-alpha and IFN-beta and was most likely mediated by antiviral enzymes as well as by an effect of these IFNs on T-cell responses. Interestingly, the lack of IFNAR and IFN-beta enhanced viral loads during acute and chronic FV infection. Exogenous IFN-alpha could be used therapeutically to reduce FV replication during acute but not chronic infection. These findings indicate that type I IFN plays an important role in the immediate antiviral defense against Friend retrovirus infection.
Institut für Virologie des Universitätsklinikum Essen, Universität Duisburg-Essen, 45122 Essen, Germany.
Nicole
N
Gerlach
Simone
S
Schimmer
Siegfried
S
Weiss
Ulrich
U
Kalinke
Ulf
U
Dittmer
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D003433:Crosses, Genetic; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D005622:Friend murine leukemia virus / Q000276:immunology* / Q000302:isolation & purification / Q000502:physiology; D007370:Interferon Type I / Q000494:pharmacology*; D016898:Interferon-alpha / Q000235:genetics / Q000494:pharmacology; D016899:Interferon-beta / Q000235:genetics / Q000494:pharmacology; D007700:Kinetics; D007942:Leukemia, Experimental / Q000276:immunology* / Q000821:virology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D017471:Receptors, Interferon / Q000172:deficiency / Q000235:genetics / Q000502:physiology; D012192:Retroviridae Infections / Q000276:immunology* / Q000821:virology; D013154:Spleen / Q000821:virology; D014412:Tumor Virus Infections / Q000276:immunology* / Q000821:virology; D019562:Viral Load; D014766:Viremia / Q000821:virology
D000998:Antiviral Agents; D007370:Interferon Type I; D016898:Interferon-alpha; D017471:Receptors, Interferon; D016899:Interferon-beta